logo

Aveo Pharmaceuticals, Inc. (AVEO)



Trade AVEO now with
  Date
  Headline
6/16/2020 11:09:58 PM AVEO Oncology Prices Underwritten Public Offering Of 8.50 Mln Shares At $5.25/shr
6/1/2020 1:37:01 PM AVEO Oncology Says FDA Accepts Filing Of NDA For Tivozanib As Treatment Of Relapsed Or Refractory Renal Cell Carcinoma
5/29/2020 7:09:54 AM AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study Of FOTIVDA In Combination With IMFINZI Advances To Phase 2
5/29/2020 7:05:33 AM AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured At ASCO 2020 Virtual Scientific Program A
4/30/2020 7:26:01 AM AVEO Oncology Q1 Net Loss $8.4 Mln Or $0.52 Per Share
3/16/2020 4:15:32 PM AVEO Oncology Q4 Loss/share $0.28 Vs. Loss $0.35 Year Ago
2/19/2020 9:12:33 AM AVEO Oncology To Effect A 1-for-10 Reverse Stock Split
1/27/2020 7:12:58 AM AVEO, Biodesix Announce Results From Phase 1b Study In Advanced Pancreatic Cancer
1/6/2020 7:05:12 AM AVEO Oncology Appoints Erick Lucera As CFO
11/19/2019 7:06:21 AM AVEO Oncology Appoints Scarlett Spring To Its Board
11/18/2019 6:03:19 AM AVEO Presents Updated OS And Subgroup Data From Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma
11/12/2019 7:21:33 AM AVEO Oncology Q3 EPS $0.10 Vs Loss $0.18 Last Year
11/4/2019 7:25:31 AM AVEO Oncology Announces Regulatory Update For Tivozanib In Renal Cell Carcinoma
9/30/2019 7:06:12 AM AVEO Oncology Begins Enrollment In Phase 1b/2 Trial On FOTIVDA In Combination With IMFINZI